Cognition Therapeutics Plans Phase III Trial for Zervimesine in DLB by Mid-2027
Cognition Therapeutics (CGTX) has announced significant progress regarding its lead drug candidate, zervimesine. The company reached an agreement with the FDA on a planned registrational trial intended to treat patients living with Dementia with Lewy Bodies (DLB). Management expects to initiate this Phase III clinical trial by mid-2027. Furthermore, the company reported a stable financial position, projecting a cash runway that extends into the fourth quarter of 2027, providing sufficient liquidity to support upcoming developmental milestones.
